06:02 GMT04 December 2020
Listen Live
    UK
    Get short URL
    by
    230
    Subscribe

    Aspirin is commonly used to reduce pain, fever, and inflammation, while also being given to those who experience strokes to reduce the risk of death. However, it is also known as a blood thinner in some that increases the risk of internal bleeding.

    A UK national clinical trial, RECOVERY, has unveiled that it will examine aspirin as a potential COVID-19 treatment, with over 16,000 patients recruited.

    "We felt it was particularly important to add aspirin to the trial since there is a clear rationale for believing that it might be beneficial and it is safe, inexpensive and widely available. We are looking for medicines for COVID-19 that can be used immediately by anyone, anywhere in the world. We do not know if aspirin is such a medicine but we will find out", said Peter Horby, a professor and co-chief investigator of the RECOVERY trial.

    According to Horby's plan, "at least 2,000 patients will be randomly allocated to receive aspirin 150 mg daily plus usual standard-of-care, and results will be compared with at least 2,000 patients who receive standard-of-care on its own". The main factor to be assessed is mortality in 28 days after, along with the need for ventilation or other impacts on hospital stay.

    "Aspirin is widely used to prevent blood clots in many other conditions, including heart attack, stroke, and pre-eclampsia in pregnant women. But enrolling patients in a randomised trial such as RECOVERY is the only way to assess whether there are clear benefits for patients with COVID-19 and whether those benefits outweigh any potential side effects such as the risk of bleeding", said Martin Landray a professor with the Nuffield Department of Population Health, a co-leader of the RECOVERY trial.

    Among other medications that are being considered by the trial group are Azithromycin, a commonly used antibiotic, an anti-inflammatory treatment, convalescent plasma collected from those recovered from COVID-19 and gained antibodies, and Regeneron's antibody cocktail REGN-COV2.

    The RECOVERY trial is supported by Oxford University and several clinical trial units, and involves medical experts from over 176 hospitals across the United Kingdom.

    As several global pharmacy companies struggle to come up with anti-coronavirus vaccine, over 49 million COVID cases have been registered in the world, with a death toll of around 1,2 million. 

    Russian-made Sputnik V is the first anti-COVID vaccine registered in the world, developed by the Gamaleya Research Institute of Epidemiology and Microbiology, and is currently completing phase 3 of clinical trials.

    Related:

    Russian Health Ministry Registers Another Two Drugs for COVID-19 Treatment
    Sputnik V to Be First COVID-19 Vaccine Presented for Registration in Israel, Hospital CEO Says
    US to Pay Hundreds of Millions for Questionable COVID-19 Antibody Treatment
    UK PM Johnson Faces Backbench Revolt if He Pushes for COVID Lockdown Extension
    Live Updates: Global Tally of COVID-19 Cases Exceeds 50Mln, According to Johns Hopkins University
    Tags:
    aspirin, clinical trial, coronavirus, COVID-19, UK
    Community standardsDiscussion